Insider Selling: Enfusion, Inc. (NYSE:ENFN) Insider Sells $35,573.88 in Stock

Enfusion, Inc. (NYSE:ENFN) insider Bronwen Bastone sold 3,126 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $35,573.88. Following the transaction, the insider now directly owns 221,875 shares in the company, valued at approximately $2,524,937.50. This trade represents a 1.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Bronwen Bastone also recently made the following trade(s):

• On Monday, March 3rd, Bronwen Bastone sold 2,064 shares of Enfusion stock. The stock was sold at an average price of $11.48, for a total transaction of $23,694.72.
• On Tuesday, January 7th, Bronwen Bastone sold 809 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total transaction of $8,195.17.

Enfusion Stock Down 0.5 %

Enfusion stock opened at $11.24 on Monday. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80. The firm’s 50-day simple moving average is $10.98 and its 200 day simple moving average is $9.90. The firm has a market capitalization of $1.44 billion, a PE ratio of 280.95, a P/E/G ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The business had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. On average, research analysts expect that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ENFN shares. Stifel Nicolaus upped their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Piper Sandler upped their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $11.13.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENFN. Harbor Capital Advisors Inc. lifted its holdings in Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares in the last quarter. Versor Investments LP purchased a new position in Enfusion in the 3rd quarter valued at about $501,000. Impax Asset Management Group plc lifted its holdings in Enfusion by 25.4% in the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after purchasing an additional 136,948 shares in the last quarter. Royce & Associates LP lifted its holdings in Enfusion by 35.4% in the 3rd quarter. Royce & Associates LP now owns 99,715 shares of the company’s stock valued at $946,000 after purchasing an additional 26,045 shares in the last quarter. Finally, Gladius Capital Management LP lifted its holdings in Enfusion by 160.5% in the 3rd quarter. Gladius Capital Management LP now owns 69,694 shares of the company’s stock valued at $661,000 after purchasing an additional 42,939 shares in the last quarter. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.